Advanced Development of Multivalent Vaccine Candidates for Filovirus and Lassa Fever
Award Notice Posted
- Solicitation number
- BAA-NIAID-NIHAI2016064
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Awarded
- to Profectus Biosciences, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HHSN272201700077C Federal contract award
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- PSC
- Not on record
- Place of performance
- TBD, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Award Notice was published by the Department of Health and Human Services National Institutes of Health on July 21, 2020. It provides funding to support the advanced development of multivalent vaccine candidates against Ebola virus, Sudan virus, Marburg virus, and optionally Lassa Fever virus, through activities such as cGMP vaccine manufacturing, completion of Phase 1, Phase 2, or Phase 1/2 clinical trials, establishing an investigational new drug application, and clinical development. Amendments to the original announcement extended the proposal deadline and clarified the scope of work to include evaluation of individual monovalent vaccine components as part of a larger multivalent program.
Notice text
3 versions
Update #3 · Latest ·
Contract Type: Cost-Plus-Fixed-Fee, Completion
Acquisition Method: Competitive - Full and Open
Update #2 ·
Amendment 2
Update #1 ·
Contracts resulting from this Broad Agency Announcement will support the advanced development of multivalent vaccine candidates against filoviruses (Ebola virus, Sudan virus, and Marburg virus) and, optionally Lassa Fever.
Files
| File | Type | Posted |
|---|---|---|
| Amendment_2_-_(BAANIAIDNIHAI2016064).pdf | ||
| Subcontract_Plan.doc | DOC document | |
| Amendment_1_-_Questions_and_Responses_(BAANIAIDNIHAI2016064).pdf | ||
| BAANIAIDNIHAI2016064_Final_4.29.16_w_attachments.pdf |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases | National Institute of Allergy and Infectious Diseases | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity